Action Potential Venture Capital

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Saluda Medical, established in 2010, is a global medical device company specializing in neuromodulation technologies. Headquartered in Australia with offices in the US and UK, the company develops and commercializes innovative, closed-loop spinal cord stimulation systems. These systems measure and adapt to the spinal cord's response to stimulation, optimizing therapy within each patient's unique therapeutic window. Saluda's primary focus is treating chronic neuropathic pain, with its devices designed to automatically adjust electrical stimulation based on real-time neurophysiological feedback, tailoring treatment to individual patient needs.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, that focuses on developing a neuromodulation technology platform aimed at treating chronic pain and other disorders affecting neuronal activity. Founded in 2017, the company is dedicated to creating a new class of therapeutic medical devices through its innovative bioelectronic medicine. This platform is designed to provide patients with effective remedies for conditions related to neural activity, positioning Presidio Medical at the forefront of advancements in medtech and bioengineering.

Saluda Medical, established in 2010, is a global medical device company specializing in neuromodulation technologies. Headquartered in Australia with offices in the US and UK, the company develops and commercializes innovative, closed-loop spinal cord stimulation systems. These systems measure and adapt to the spinal cord's response to stimulation, optimizing therapy within each patient's unique therapeutic window. Saluda's primary focus is treating chronic neuropathic pain, with its devices designed to automatically adjust electrical stimulation based on real-time neurophysiological feedback, tailoring treatment to individual patient needs.

Onc.AI, Inc. is a San Carlos, California-based company founded in 2020 that focuses on clinical oncology. It specializes in leveraging advanced technologies such as deep learning to enhance oncology diagnostics by providing insights derived from clinical oncology data, genomics, proteomics, and radiomics. The company's comprehensive approach aims to improve treatment outcomes by offering actionable insights that aid in the decision-making process for healthcare professionals in the oncology field.

Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Exo is a medical device startup focused on revolutionizing ultrasound technology for imaging and therapeutic applications. The company has developed a handheld ultrasound platform that integrates advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost advantages of semiconductor manufacturing. This approach allows Exo to provide high-quality, affordable, and user-friendly medical imaging solutions. By enabling healthcare professionals to make critical, real-time decisions, Exo aims to enhance patient outcomes significantly. The company's commitment to accessibility and ease of use in medical imaging represents a significant advancement in the field, making effective diagnostic tools available at an unprecedented price point.

Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, that focuses on developing a neuromodulation technology platform aimed at treating chronic pain and other disorders affecting neuronal activity. Founded in 2017, the company is dedicated to creating a new class of therapeutic medical devices through its innovative bioelectronic medicine. This platform is designed to provide patients with effective remedies for conditions related to neural activity, positioning Presidio Medical at the forefront of advancements in medtech and bioengineering.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Axon Therapies specializes in developing innovative healthcare devices aimed at addressing heart failure by targeting the sympathetic nervous system. The company's primary offering is the SAVM procedure, which employs a small catheter inserted through the groin to ablate the right greater splanchnic nerve. This technique effectively reduces sympathetic nerve activity, helping to restore balance in the circulatory system. By shifting blood volume from the heart to the splanchnic bed, it alleviates pressure in the heart, thereby enhancing treatment efficacy. Clinicians can utilize this approach to initiate patient care rapidly, increasing the likelihood of successful outcomes.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, that focuses on developing a neuromodulation technology platform aimed at treating chronic pain and other disorders affecting neuronal activity. Founded in 2017, the company is dedicated to creating a new class of therapeutic medical devices through its innovative bioelectronic medicine. This platform is designed to provide patients with effective remedies for conditions related to neural activity, positioning Presidio Medical at the forefront of advancements in medtech and bioengineering.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Saluda Medical, established in 2010, is a global medical device company specializing in neuromodulation technologies. Headquartered in Australia with offices in the US and UK, the company develops and commercializes innovative, closed-loop spinal cord stimulation systems. These systems measure and adapt to the spinal cord's response to stimulation, optimizing therapy within each patient's unique therapeutic window. Saluda's primary focus is treating chronic neuropathic pain, with its devices designed to automatically adjust electrical stimulation based on real-time neurophysiological feedback, tailoring treatment to individual patient needs.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.